Xenetic Biosciences and PeriNess Collaborate on Exploratory Clinical Study
Xenetic Biosciences, Inc., a trailblazing biopharmaceutical company specializing in the development of innovative immuno-oncology technologies to tackle challenging cancers, recently announced a significant collaboration with PeriNess Ltd. this March.
Collaborative Study at Tel-Aviv Sourasky Medical Center
Under the terms of the Clinical Study Agreement, PeriNess will support Xenetic in an investigator-initiated study at the Tel-Aviv Sourasky Medical Center. The study will focus on Xenetic’s systemic DNase I candidate, XBIO-015, which holds potential for treating relapsed or refractory osteosarcoma and Ewing sarcoma.
What is XBIO-015?
XBIO-015 is a DNase I enzyme designed to target and destroy extracellular DNA (eDNA) that forms a protective shield around cancer cells. By neutralizing eDNA, XBIO-015 may help the immune system better recognize and attack cancer cells.
Impact on the Individual
For individuals diagnosed with relapsed or refractory osteosarcoma or Ewing sarcoma, this study represents a beacon of hope. If successful, XBIO-015 could offer a new treatment option for these patients, potentially improving their quality of life and increasing their chances of recovery.
Global Implications
The collaboration between Xenetic and PeriNess could have far-reaching implications for the global oncology community. If XBIO-015 proves effective in treating osteosarcoma and Ewing sarcoma, it could pave the way for new treatments for various types of cancer. Additionally, it could strengthen the partnership between Xenetic and PeriNess, potentially leading to further collaborations and advancements in the field of immuno-oncology.
Conclusion
Xenetic Biosciences’ collaboration with PeriNess on the exploratory clinical study of XBIO-015 marks an essential step forward in the quest to develop innovative immuno-oncology treatments for difficult-to-treat cancers like osteosarcoma and Ewing sarcoma. This endeavor offers renewed hope for patients, and if successful, could have significant implications for the global oncology community.
- Xenetic Biosciences collaborates with PeriNess to study XBIO-015 at Tel-Aviv Sourasky Medical Center
- XBIO-015 is a DNase I enzyme designed to target and destroy extracellular DNA around cancer cells
- The study focuses on treating relapsed or refractory osteosarcoma and Ewing sarcoma
- Success could lead to new treatment options for patients and potential implications for the global oncology community
